Salvage therapy in patients with advanced non-small cell lung cancer

被引：11

作者：

Bedano, Pablo M. ^{[1
]}

Hanna, Nasser H. ^{[1
]}

机构：

[1] Indiana Univ, Sch Med, Dept Med, Div Oncol, Indianapolis, IN 46202 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2006年 / 1卷 / 06期

关键词：

D O I：

10.1097/01243894-200607000-00015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with advanced non-small cell lung cancer continue to have a poor prognosis; most die from the disease within I year. Chemotherapy is beneficial for some patients in the first-line metastatic setting. Three agents, namely docetaxel, pemetrexed, and erlotinib, are approved by the United States Food and Drug Administration as treatment in the second-line setting. In this article, we examine the data supporting the use of these agents in the second-line setting and review data from other completed trials. Lastly, we propose strategies to advance the treatment of patients with non-small cell lung cancer.

引用

页码：582 / 587

页数：6

共 50 条

[1]

ALBERTI W, 1995, BRIT MED J, V311, P899

[2]

*AM CANC SOC, 2006, CANC FACTS FIG 2005

[3] ErbB-targeted therapeutic approaches in human cancer [J].

Arteaga, CL .

EXPERIMENTAL CELL RESEARCH, 2003, 284 (01) :122-130

[4]

Bruns CJ, 2000, CANCER RES, V60, P2926

[5] Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer:: a Spanish Lung Cancer Group trial [J].

Camps, C ;

Massuti, B ;

Jiménez, A ;

Maestu, I ;

Gómez, RG ;

Isla, D ;

González, JL ;

Almenar, D ;

Blasco, A ;

Rosell, R ;

Carrato, A ;

Viñolas, N ;

Batista, N ;

Girón, CG ;

Galán, A ;

López, M ;

Blanco, R ;

Provencio, M ;

Diz, P ;

Felip, E .

ANNALS OF ONCOLOGY, 2006, 17 (03) :467-472

[6] Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway [J].

Clarke, K ;

Smith, K ;

Gullick, WJ ;

Harris, AL .

BRITISH JOURNAL OF CANCER, 2001, 84 (10) :1322-1329

[7]

CLARKE S, 2003, ANN ONCOL, V14, P455

[8] TOPOISOMERASE-I INHIBITORS - TOPOTECAN AND IRENOTECAN [J].

CREEMERS, GJ ;

LUND, B ;

VERWEIJ, J .

CANCER TREATMENT REVIEWS, 1994, 20 (01) :73-96

[9] Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial [J].

Dancey, J ;

Shepherd, FA ;

Gralla, RJ ;

Kim, YS .

LUNG CANCER, 2004, 43 (02) :183-194

[10]

DEMETRI G, 2006, P AM SOC CLIN ONCOL

← 1 2 3 4 5 →